Admission of Shares and Total Voting Rights

Oxford, UK - 20 August 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today provides an update to the announcement made on 15 August 2025 regarding the successful Placing and Subscription of new Ordinary Shares.

The Company confirms that 13,921,114 new Ordinary Shares of 50 pence each will be admitted at 8.00 a.m. (London time) today to the Equity Shares (Commercial Companies) segment of the Official List and to trading on the Main Market of the London Stock Exchange (the "Admission").

Following the Admission, the Company's issued share capital will consist of 120,173,462 ordinary shares of 50 pence each ("Ordinary Shares"), and there will remain no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in OXB at the date of this notice, following the Admission,  is 120,173,462.

The above figure 120,173,462 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, OXB under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

Enquiries:       

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.